Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Inspire Pharmaceuticals |
---|---|
Information provided by: | Inspire Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00564421 |
The purpose of this study is to determine the safety and efficacy of epinastine nasal spray compared to placebo for the treatment of subjects with seasonal allergic rhinitis
Condition | Intervention | Phase |
---|---|---|
Seasonal Allergic Rhinitis |
Drug: epinastine nasal spray, low concentration, low dose volume Drug: placebo nasal spray Drug: epinastine nasal spray, low concentration, high dose volume Drug: epinastine nasal spray, high concentration, low dose volume Drug: epinastine nasal spray, high concentration, high dose volume |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment |
Official Title: | A Phase 3 Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple Dose Safety and Efficacy Study of Epinastine Nasal Spray vs. Placebo in Subjects With Seasonal Allergic Rhinitis |
Enrollment: | 798 |
Study Start Date: | November 2007 |
Study Completion Date: | April 2008 |
Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: epinastine nasal spray, low concentration, low dose volume
2 sprays in each nostril, dosed twice a day
|
2: Experimental |
Drug: epinastine nasal spray, low concentration, high dose volume
2 sprays in each nostril, dosed twice a day
|
3: Experimental |
Drug: epinastine nasal spray, high concentration, low dose volume
2 sprays in each nostril, dosed twice a day
|
4: Experimental |
Drug: epinastine nasal spray, high concentration, high dose volume
2 sprays in each nostril, dosed twice a day
|
5: Placebo Comparator |
Drug: placebo nasal spray
2 sprays in each nostril, dosed twice a day
|
Ages Eligible for Study: | 12 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
Allergy Asthma Research Institute | |
Waco, Texas, United States, 76712 | |
Diagnostics Research Group | |
San Antonio, Texas, United States, 78229 | |
Allergy & Asthma Research Center, P.A. | |
San Antonio, Texas, United States, 78229 | |
Central Texas Health Research | |
New Braunfels, Texas, United States, 78130 | |
Allergy & Asthma Associates | |
Austin, Texas, United States, 78731 | |
Biogenics Research Institute | |
San Antonio, Texas, United States, 78229 | |
Kerrville Research Associates, P.A. | |
Kerrville, Texas, United States, 78028 | |
Sylvana Research Associates | |
San Antonio, Texas, United States, 78229 | |
Lovelace Scientific Resources, Inc. | |
Austin, Texas, United States, 78759 |
Study Director: | Donald Kellerman, PharmD | Inspire Pharmaceuticals |
Responsible Party: | Inspire Pharmaceuticals ( Amy Schaberg, BSN, Vice President Respiratory Clinical Research ) |
Study ID Numbers: | 033-103 |
Study First Received: | November 27, 2007 |
Last Updated: | May 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00564421 |
Health Authority: | United States: Food and Drug Administration |
Hypersensitivity Otorhinolaryngologic Diseases Respiratory Tract Infections Respiratory Tract Diseases Rhinitis, Allergic, Seasonal Hypersensitivity, Immediate |
Histamine phosphate Rhinitis Histamine Epinastine Respiratory Hypersensitivity |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Histamine Antagonists Immune System Diseases Physiological Effects of Drugs |
Histamine Agents Histamine H1 Antagonists Pharmacologic Actions Nose Diseases |